ECSP11011171A - Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos - Google Patents

Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos

Info

Publication number
ECSP11011171A
ECSP11011171A EC2011011171A ECSP11011171A ECSP11011171A EC SP11011171 A ECSP11011171 A EC SP11011171A EC 2011011171 A EC2011011171 A EC 2011011171A EC SP11011171 A ECSP11011171 A EC SP11011171A EC SP11011171 A ECSP11011171 A EC SP11011171A
Authority
EC
Ecuador
Prior art keywords
modified
vsp
protozoo
vaccine
expressing
Prior art date
Application number
EC2011011171A
Other languages
English (en)
Inventor
Hugo Daniel Lujan
Original Assignee
Consejo Nac Invest Cient Tecnicas
Univ Catolica De Cordova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tecnicas, Univ Catolica De Cordova filed Critical Consejo Nac Invest Cient Tecnicas
Publication of ECSP11011171A publication Critical patent/ECSP11011171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Protozoos parásitos modificados que comprenden la expresión simultánea en su superficie de al menos dos proteínas variables de superficie (VSP). Los protozoos modificados pueden también expresar en forma simultánea el repertorio completo de proteínas variables de superficie. Los protozoos muestran una expresión reducida de las enzimas Dicer, ARN polimerasa RNA dependiente (RdRP) o ambas, en donde el gen RdRP y/o el gen Dicer ha sido silenciado. El protozoo puede ser cualquier protozoo que presente un mecanismo de variación antigénica.
EC2011011171A 2008-12-02 2011-07-01 Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos ECSP11011171A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11905808P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
ECSP11011171A true ECSP11011171A (es) 2011-09-30

Family

ID=42233679

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011171A ECSP11011171A (es) 2008-12-02 2011-07-01 Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos

Country Status (18)

Country Link
US (1) US9463229B2 (es)
EP (1) EP2364156B1 (es)
JP (3) JP2012510286A (es)
CN (1) CN102281884B (es)
AR (1) AR074458A1 (es)
AU (1) AU2009323734B2 (es)
BR (1) BRPI0917075B1 (es)
CA (1) CA2745470C (es)
CL (2) CL2011001309A1 (es)
CO (1) CO6390115A2 (es)
CR (1) CR20110377A (es)
EC (1) ECSP11011171A (es)
ES (1) ES2667773T3 (es)
MX (2) MX2011005815A (es)
NZ (2) NZ604943A (es)
PE (2) PE20110942A1 (es)
PT (1) PT2364156T (es)
WO (1) WO2010064204A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
EP4566624A1 (en) 2023-12-04 2025-06-11 VacciMed-Oral GmbH Vaccines against protozoan parasites

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
JP2000083677A (ja) * 1998-09-17 2000-03-28 Bayer Ltd ダニワクチン
GB0000474D0 (en) * 2000-01-10 2000-03-01 Inal Jameel M Receptor

Also Published As

Publication number Publication date
EP2364156A2 (en) 2011-09-14
JP2012510286A (ja) 2012-05-10
AU2009323734A1 (en) 2010-06-10
MX351579B (es) 2017-10-20
NZ593106A (en) 2013-05-31
PT2364156T (pt) 2018-04-24
PE20150889A1 (es) 2015-06-07
CA2745470C (en) 2018-09-25
CN102281884B (zh) 2015-09-30
CR20110377A (es) 2011-10-20
BRPI0917075B1 (pt) 2019-11-12
NZ604943A (en) 2014-08-29
US20120093871A1 (en) 2012-04-19
AR074458A1 (es) 2011-01-19
WO2010064204A2 (en) 2010-06-10
MX2011005815A (es) 2011-09-30
CA2745470A1 (en) 2010-06-10
CO6390115A2 (es) 2012-02-29
WO2010064204A3 (en) 2010-12-02
CL2011001309A1 (es) 2012-03-16
ES2667773T3 (es) 2018-05-14
US9463229B2 (en) 2016-10-11
CN102281884A (zh) 2011-12-14
BRPI0917075A2 (pt) 2016-08-02
PE20110942A1 (es) 2011-12-30
AU2009323734B2 (en) 2016-06-30
JP6793621B2 (ja) 2020-12-02
JP2018024700A (ja) 2018-02-15
EP2364156B1 (en) 2018-01-31
CL2018002834A1 (es) 2019-04-05
JP2016000045A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
CY1124644T1 (el) Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων
CL2024001734A1 (es) Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2023012263A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
ECSP12011685A (es) Inmunoconjugados dirigidos
CO6410304A2 (es) Combinación de un inhibidor de nucleósido polimerasa con un inhibidor de proteasa macrocíclica y su uso en el tratamiento de hepatitis c, fibrosis hepática y función hepática alterada
CY1119273T1 (el) Προπανοϊκου (s)-ισοπροπυλιου
CR20200461A (es) Método para tratar las enfermedades asociadas al vph
MX2020002885A (es) Derivados de galnac.
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
CO6331372A2 (es) Inhibidor de parp 4-yodo-3-nitrobenzamida o un metabolito de la misma
CO2018004937A2 (es) Células asesinas naturales y células ilc3 y usos de las mismas
AR093291A1 (es) Celulas con genes neuroendocrinos modificados
MX2016005959A (es) Métodos para diagnosticar enfermedades infecciosas usando medio de adsorción.
MX2019013370A (es) Constructos de anticuerpos de ácidos nucleicos optimizados.
CO6280048A1 (es) Artículo absorbente que incluye un núcleo que tiene una pluralidad de primeras regiones y una segunda región alrededor de las primeras regiones.
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
BRPI0909566A2 (pt) Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante
CO2025006500A2 (es) Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas
CL2018002834A1 (es) Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309)
EA201100902A1 (ru) Новый способ получения рнк-вируса
UY30042A1 (es) Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
ES2479540T3 (es) Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades
AR093447A1 (es) Enriquecimiento de plasmablastos especificos de antigeno